Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andecaliximab - Gilead Sciences

Next Previous
Drug Profile

Andecaliximab - Gilead Sciences

Alternative Names: Anti-matrix metalloproteinase-9 monoclonal antibody; Anti-MMP9 monoclonal antibody; GS-5745

Latest Information Update: 30 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer ashibio; Gilead Sciences
  • Class Antineoplastics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Fibrodysplasia ossificans progressiva
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Gastric cancer; Glioblastoma; Rheumatoid arthritis; Solid tumours; Ulcerative colitis

Most Recent Events

  • 23 Jan 2025 US FDA grantes a Rare Pediatric Disease Designation (RPDD) to Andecaliximab in Fibrodysplasia Ossificans Progressive, before January 2025
  • 25 Oct 2024 Phase-II/III clinical trials in Fibrodysplasia ossificans progressiva in USA (SC) (NCT06508021)
  • 17 Sep 2024 ashibio plans a phase II/III trial for Fibrodysplasia ossificans progressiva in the second half of 2024 (NCT06508021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top